Research Fellow

New York City, New York (US)
NIH base salary
February 13 2017
Position Type
Full Time

The Barbara & Donald Jonas Stem Cell and Regenerative Medicine Laboratory supported by NIH and New York State, seeks postdoctoral applicant for genome ed with patient-specific stem cell lines: disease modeling, repair, transplantation as well as therapeutic editing (Departments of Ophthalmology, Pathology & Cell Biology at Columbia University).

References on Stem Cells: Human Molecular Genetics. 2014 Jan 31. PMID: 24497574; Transplantation. 89(8), 911-9. Mol Med. 2012 18:1312-9. Book: Tsang, S.H., ed. (2012). Stem Cell Biology and Regenerative Medicine in Ophthalmology (New York: Springer).

References on Gene Therapy: J Clin Invest. PMID 26301813 Human Molecular Genetics. PMID: 24101599; PMID: 23108158; J Neurosci. PMID: 23946405. Science. 272, 1026-1029  PMID: 8638127; Science. 282, 117-21. PMID: 9756475

Retinal degenerative diseases affect nine million Americans, including 6.5% of Americans older than 40 years of age. Other than cancer, blindness is the most feared of condition amongst Americans. Our New York State and NIH supported program investigates cell-based treatments for retinal diseases, and develops patient specific disease models relevant to drug development. The eye is an ideal testing ground for stem cell therapies because of its relative immune privilege and its ready accessibility for monitoring and imaging purposes. In the eye, various assays can be used to non-invasively quantify transplanted tissue at multiple time points. Furthermore, insight gained from the study of retinal disorders is applicable to other diseases and organ systems, thereby promoting the development of novel stem cell- and gene-based cures for a broad array of previously incurable maladies.

For example, in retinal gene therapy, the laboratory provided the preclinical feasibility data for an upcoming human trial. For cell therapy, laboratory was the first to restore visual function in mice using human induced pluripotent stem (iPS) cells – and to do so without inducing tumor formation. These achievements depended on novel preclinical models generated in the laboratory, including gene-targeted humanized mice and human iPS-derived cells – both with patient-specific mutations. The team also developed the first patient-specific model for an age-related retinal disease.

Requirements: Applicants should have a PhD in enzyme kinetics, electrophysiology, genome engineering, Molecular Biology or related fields. U.S. citizen/permanent residents preferred.

Please email your CV to